New principles of treatment of vaginal dysbiosis in reproductive aged womеn

Abstract

Purpose of the study. To investigate the efficiency and safety of combined treatment and prevention of bacterial vaginosis recurrence in women of reproductive age. Materials and methods. 78 women of reproductive age with diagnosed bacterial vaginosis were examined. 50 women are included in the main group, 28 women are included in the comparison group. Women in the main group were offered complex therapy: Samitol (secnidazole 500 mg) 1 g 2 times a day per os for 3 days, Gynex Forte (1 vaginal suppository contains metronidazole 750 mg, miconazole nitrate 200 mg) 1 time a day (overnight) for 7 days, Serrata (serratiopeptidase tablets) 1 tablet (10 mg) 3 times a day for 20 days. After Gynex Forte treatment women received a probiotic per vaginum for 7 days. Comparison group received standard two-step therapy. Results. Clinical effect of treatments was achieved in 49 (98%) patients of the main group in contrast to the comparison group where the effectiveness of treatment was 12 (42.9%). A direct positive treatment effect on 15th day in the main group was reported in 33 cases (66%) compared with control group – 9 (32.1%). 6 months after treatment main group did not have recurrence of bacterial vaginosis, while in the comparison group recurrence was diagnosed in 8 (28.6%) women. Conclusions. The results showed the high efficacy and safety of complex therapy, which included drug Samitol (secnidazole), vaginal suppositories Gynex Forte (a combination of metronidazole and miconazole) and proteolytic drug Serrata (serratiopeptidase tablets) in women of reproductive age in the bacterial vaginosis treatment. The results of this clinical study suggest the recommended treatment of bacterial vaginosis in women of reproductive age for common use in gynecological practice

Keywords

• reproductive age
• vaginal dysbiosis
• bacterial vaginosis
• antimicrobial drugs
• combined treatment
• recurrence prevention